Immunotherapy for birch tree pollen allergy
The National Institute for Health and Care Excellence has recommended the first under-the-tongue tablet immunotherapy shown to build long-term tolerance to allergens, which could help up to 27,000 people in England with moderate to severe birch tree pollen allergies. The treatment, betula verrucosa (Itulazax 12 SQ-Bet) which is made by Alk-Abelló, for severe hay fever (allergic rhinitis or conjunctivitis), offers the potential for long-term rather than temporary symptom relief for this debilitating condition.